Alliance Pharma Reports Steady Growth in 2024

Alliance Pharma (GB:APH) has released an update.

Alliance Pharma PLC has reported a robust financial performance for the first half of 2024, with revenues rising to £84.8 million, a 2.8% increase from the previous year, and a steady gross profit growth of 8.1%. Key growth drivers included the Kelo-Cote franchise and a strong performance in the US market, despite a downturn in Nizoral and Amberen sales. The company’s strategic investments in marketing and innovation are expected to continue to deliver strong free cash flow and reduce net debt by year-end.

For further insights into GB:APH stock, check out TipRanks’ Stock Analysis page.